Cumberland Pharmaceuticals Announces New Vibatv Pediatric Publication Highlights Its Safety In Patients 2 To 17 Years Of Age
Portfolio Pulse from Benzinga Newsdesk
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has announced a new publication detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ® (telavancin) injection in children aged 2 to 17. The study found that a single 10 mg/kg dose of Vibativ was safe with no serious adverse events or renal concerns. Vibativ is an intravenous antibiotic approved by the FDA for the treatment of certain bacterial infections in adults.
October 10, 2023 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cumberland Pharmaceuticals' Vibativ has been found safe for use in children aged 2 to 17, potentially expanding its market.
The successful clinical study of Vibativ in children could potentially expand its market, leading to increased sales and revenue for Cumberland Pharmaceuticals. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100